Bellevue Life Sciences Ac... (BLAC)
NASDAQ: BLAC
· Real-Time Price · USD
3.01
-3.72 (-55.27%)
At close: Feb 14, 2025, 3:53 PM
Bellevue Life Sciences Acquisition Income Statement
Financials in USD. Fiscal
year is
January - December.
| Fiscal Year | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 | Q2 2022 | Q1 2022 | Q4 2021 | Q3 2021 | Q2 2021 | Q1 2021 |
| Period Ending | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | Dec 31, 2021 | Sep 30, 2021 | Jun 30, 2021 | Mar 31, 2021 |
Revenue | 761.27K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost of Revenue | 592.59K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Gross Profit | 168.69K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Income | -2.92M | -2.14M | -454K | -476K | -451K | -862K | -410K | -280K | -278K | -14.25K | -20.02K | -988 | -126 | -322 | -119 | -2.74K | -124 |
Interest Income | 4.32K | -1.21M | 269.2K | 465.5K | 480.82K | 928.76K | 618.5K | 810.3K | 417.73K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Pretax Income | -11.39M | -1.95M | -185K | -10.04K | 30.04K | 66.87K | 208.07K | 530.03K | 139.63K | -14.25K | -20.02K | -988 | -126 | -322 | -119 | -2.74K | -124 |
Net Income | -11.39M | -2.02M | -231K | -97.3K | -60.43K | -86.17K | 78.18K | 301.46K | 110.31K | -14.25K | -20.02K | -988 | -126 | -322 | -119 | -2.74K | -124 |
Selling & General & Admin | 3.09M | 2.14M | 454.13K | 475.54K | 450.78K | 861.89K | 410.43K | 280.27K | 278.1K | 14.25K | 20.02K | 988.00 | 126.00 | 322.00 | 119.00 | 2.74K | 124.00 |
Research & Development | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Other Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Operating Expenses | 3.09M | 2.14M | 454.13K | 475.54K | 450.78K | 861.89K | 410.43K | 280.27K | 278.1K | 14.25K | 20.02K | 988.00 | 126.00 | 322.00 | 119.00 | 2.74K | 124.00 |
Interest Expense | -16.4K | -43.01K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Selling & Marketing Expenses | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Cost & Expenses | 3.68M | 2.14M | 454.13K | 475.54K | 450.78K | 861.89K | 410.43K | 280.27K | 278.1K | 14.25K | 20.02K | 988.00 | 126.00 | 322.00 | 119.00 | 2.74K | 124.00 |
Income Tax Expense | n/a | -519K | 46.03K | 87.26K | 90.47K | 153.04K | 129.88K | 228.56K | 29.32K | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
Shares Outstanding (Basic) | 4.48M | 4.48M | 4.04M | 4.04M | 5.62M | 7.41M | 9.05M | 9.05M | 9.05M | 9.05M | 7.93M | 7.93M | 7.93M | 7.89M | 7.93M | 7.89M | 7.89M |
Shares Outstanding (Diluted) | 4.48M | 4.48M | 4.04M | 4.04M | 5.62M | 7.41M | 9.05M | 9.05M | 9.05M | 9.05M | 7.93M | 7.93M | 7.93M | 7.89M | 7.93M | 7.89M | 7.89M |
EPS (Basic) | -2.54 | -0.45 | -0.06 | -0.02 | -0.01 | -0.01 | 0.01 | 0.03 | 0.01 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 |
EPS (Diluted) | -2.54 | -0.45 | -0.06 | -0.02 | -0.01 | -0.01 | 0.01 | 0.03 | 0.01 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 | -0.00 |
EBITDA | -2.92M | -2.63M | -454K | -476K | -451K | -862K | -410K | -280K | -278K | -14.25K | -20.02K | -988 | -126 | -322 | -119 | -2.74K | -124 |
EBIT | n/a | 1.38M | -454K | -476K | -451K | -862K | -410K | -280K | -278K | -14.25K | -20.02K | -988 | -126 | -322 | -119 | -2.74K | -124 |
Depreciation & Amortization | n/a | -43.28K | n/a | n/a | 43.28K | 43.81K | -39.59K | 122.08K | 41.58K | 21.14K | 27.08K | n/a | n/a | n/a | n/a | n/a | n/a |